Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DGAP-Adhoc : Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough

08/03/2021 | 08:21am EDT
DGAP-Ad-hoc: Evotec SE / Key word(s): Study results 
Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough 
03-Aug-2021 / 14:19 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announces that 
the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy 
and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic 
cough. The underlying molecule is a P2X3 receptor antagonist in Bayer's clinical development pipeline originating from 
a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically 
significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound 
recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile. 
Under the agreement from 2012, Evotec would be entitled to its next financial milestone payment upon start of a Phase 
III clinical study, to be decided by Bayer. 
More details of the study will be presented by Bayer. 
- End of ad hoc release - 
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, 
Germany, Phone: +49.(0)40.560 81-242, werner.lanthaler@evotec.com 
=---------------------------------------------------------------------------------------------------------------------- 
03-Aug-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and 
Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
              Germany 
Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1223677 
 
End of Announcement  DGAP News Service 
=------------ 

1223677 03-Aug-2021 CET/CEST

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1223677&application_name=news 
 

(END) Dow Jones Newswires

August 03, 2021 08:20 ET (12:20 GMT)

All news about EVOTEC SE
10/11PASITHEA THERAPEUTICS : Partners With Evotec for Drug Development Project
MT
10/11EVOTEC : expands neuroscience collaboration with Bristol Myers Squibb to include novel cel..
AQ
10/11EVOTEC : LUMITOS AG - Evotec expands neuroscience collaboration with Bristol Myers Squibb ..
AQ
10/11EVOTEC : Plans Offering, Secondary Listing Of American Depositary Shares
MT
10/11EVOTEC : files registration statement for proposed offering of American Depositary Shares
PU
10/11EVOTEC : files registration statement for proposed offering of American Depositary Shares
EQ
10/11PRESS RELEASE : Evotec SE files registration statement for proposed offering of American D..
DJ
10/08Evotec Files for Initial Public Offering in the U.S.
DJ
10/08EVOTEC : To Study New Cell Types In $9 Million Collaboration With US Pharma Group
MT
10/08EVOTEC : expands neuroscience collaboration with Bristol Myers Squibb to include novel cel..
PU
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2021 564 M 654 M 654 M
Net income 2021 74,0 M 85,9 M 85,9 M
Net Debt 2021 61,0 M 70,8 M 70,8 M
P/E ratio 2021 91,3x
Yield 2021 -
Capitalization 6 850 M 7 947 M 7 946 M
EV / Sales 2021 12,3x
EV / Sales 2022 10,7x
Nbr of Employees 3 914
Free-Float 87,9%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 41,55 €
Average target price 40,01 €
Spread / Average Target -3,70%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Iris L÷w-Friedrich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE37.22%7 947
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414